Loading patent…
AssigneeTaiMed Biologics, Inc.
InventorsJames Nienyuan Chang, Hsiang-Fa Liang, Meng-Hsin Chen, Kuei-Ling Kuo, An-Chieh Li
Estimating the term…
Disclosed herein is a long acting pharmaceutical composition for treating or preventing human immunodeficiency virus (HIV) infection. The pharmaceutical composition comprises a suspension of a lysine-based aspartyl protease inhibitor or salt thereof, a surface modifier, and a pharmaceutically acceptable carrier; wherein the lysine-based aspartyl protease inhibitor or salt thereof has an average effective particle size of less than about 500 nm. A method for treating or preventing HIV infection with the pharmaceutical composition is also disclosed.
A long acting pharmaceutical composition for treating human immunodeficiency virus (HIV) infection, which consists of a suspension of a lysine-based aspartyl protease inhibitor or salt thereof, a surface modifier, wherein the surface modifier is selected from the group consisting of poloxamer 188, poloxamer 407, d-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS or Vitamin E TPGS), Polysorbate 80 (Tween 80), and distearoyl phosphatidyl-ethanolamine-poly(ethylene glycol) (DSPE-PEG), and a pharmaceutically acceptable carrier;
A method of treating HIV infection for a long term comprising administering to a subject in need thereof by intramuscular or subcutaneous injection once a week to once a month a therapeutically effective amount of a pharmaceutical composition consisting of a suspension of a lysine-based aspartyl protease inhibitor or salt thereof, a surface modifier, and a pharmaceutically acceptable carrier;
Dependencies are inferred from the claim text.